Translational Research: Biomarkers & Diagnostics

Access ESMO scientific and educational resources on

  • Translational Research
  • Biomarkers
  • Diagnostics

Recent medwireNews and resources from conferences are for ESMO Members only.

Tumour Knowledge Portal

Preselected recommended educational resources on this topic

Reporting from ASCO 2018, Mark Ladanyi explains that tumour mutation burden (TMB) is emerging after PD-L1 as a major biomarker of response to immune checkpoints inhibitors. We need to learn more about patients status regarding TMB and PD-L1 across tumour types and two studies addressing this question were presented at this meeting.